4563 Stock Overview
A biopharmaceutical company, engages in the research and development of gene-based medical products.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
AnGes, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥45.00 |
52 Week High | JP¥117.00 |
52 Week Low | JP¥44.00 |
Beta | 0.59 |
11 Month Change | -4.26% |
3 Month Change | -31.82% |
1 Year Change | -59.46% |
33 Year Change | -95.07% |
5 Year Change | -93.68% |
Change since IPO | -97.43% |
Recent News & Updates
Recent updates
Shareholder Returns
4563 | JP Biotechs | JP Market | |
---|---|---|---|
7D | 0% | -3.6% | 1.5% |
1Y | -59.5% | -17.7% | 18.8% |
Return vs Industry: 4563 underperformed the JP Biotechs industry which returned -17.7% over the past year.
Return vs Market: 4563 underperformed the JP Market which returned 18.8% over the past year.
Price Volatility
4563 volatility | |
---|---|
4563 Average Weekly Movement | 4.2% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 7.4% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4563's share price has been volatile over the past 3 months.
Volatility Over Time: 4563's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
4563 fundamental statistics | |
---|---|
Market cap | JP¥10.31b |
Earnings (TTM) | -JP¥6.35b |
Revenue (TTM) | JP¥249.00m |
41.4x
P/S Ratio-1.6x
P/E RatioIs 4563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4563 income statement (TTM) | |
---|---|
Revenue | JP¥249.00m |
Cost of Revenue | JP¥151.00m |
Gross Profit | JP¥98.00m |
Other Expenses | JP¥6.45b |
Earnings | -JP¥6.35b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 09, 2024
Earnings per share (EPS) | -27.73 |
Gross Margin | 39.36% |
Net Profit Margin | -2,550.20% |
Debt/Equity Ratio | 0% |
How did 4563 perform over the long term?
See historical performance and comparison